QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
Positive News SentimentPositive News
NASDAQ:URGN

UroGen Pharma (URGN) Earnings Date, Estimates & Call Transcripts

$13.87
+0.18 (+1.31%)
(As of 10/3/2023 ET)
Compare
Today's Range
$13.58
▼
$14.52
50-Day Range
$9.01
▼
$22.64
52-Week Range
$7.07
▼
$24.13
Volume
295,687 shs
Average Volume
326,714 shs
Market Capitalization
$325.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Nov. 9Estimated
Actual EPS
(Aug. 10)
-$1.03 Beat By $0.10
Consensus EPS
(Aug. 10)
-$1.13
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

URGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

URGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

UroGen Pharma Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($1.29)($1.29)($1.29)
Q2 20232($1.14)($1.12)($1.13)
Q3 20232($1.22)($0.78)($1.00)
Q4 20232($1.11)($0.57)($0.84)
FY 20238($4.76)($3.76)($4.26)
Q1 20241($0.55)($0.55)($0.55)
Q2 20241($0.50)($0.50)($0.50)
Q3 20241($0.39)($0.39)($0.39)
Q4 20241($0.28)($0.28)($0.28)
FY 20244($1.72)($1.72)($1.72)

URGN Earnings Date and Information

UroGen Pharma last released its earnings data on August 10th, 2023. The reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.13) by $0.10. The company earned $21.14 million during the quarter, compared to analysts' expectations of $19.90 million. UroGen Pharma has generated ($4.68) earnings per share over the last year (($4.68) diluted earnings per share). Earnings for UroGen Pharma are expected to grow in the coming year, from ($3.60) to ($2.41) per share. UroGen Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off prior year's report dates.

UroGen Pharma Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/9/2023
Estimated)		------- 
8/10/2023Q2 2023($1.13)($1.03)+$0.10($1.03)$19.90 million$21.14 million
5/11/2023Q1 2023($1.39)($1.30)+$0.09($1.30)$16.55 million$17.19 million
3/16/2023Q4 2022($1.12)($1.22)($0.10)($1.22)$18.25 million$18.09 million
11/10/2022Q3 2022($1.22)($1.13)+$0.09($1.13)$20.30 million$16.10 million    
8/11/2022Q2 2022($1.33)($1.18)+$0.15($1.18)$16.95 million$16.60 million
5/10/2022Q1 2022($1.36)($1.25)+$0.11($1.25)$15.62 million$13.56 million
3/21/2022Q4 2021($1.18)($1.27)($0.09)($1.27)$16.15 million$16.17 million    
11/15/2021Q3 2021($1.26)($1.35)($0.09)($1.35)$15.90 million$11.35 million    
8/4/2021Q2 2021($1.10)($1.17)($0.07)($1.17)$13.00 million$13.03 million    
5/13/2021Q1 2021($1.26)($1.17)+$0.09($1.17)$8.41 million$7.49 million  
3/17/2021Q4 2020($1.37)($1.38)($0.01)($1.38)$7.21 million$7.97 million  
11/9/2020Q3 2020($1.47)($1.31)+$0.16($1.31)$3.21 million$3.46 million  












UroGen Pharma Earnings - Frequently Asked Questions

When is UroGen Pharma's earnings date?

UroGen Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off last year's report dates. Learn more on URGN's earnings history.

Did UroGen Pharma beat their earnings estimates last quarter?

In the previous quarter, UroGen Pharma (NASDAQ:URGN) reported ($1.03) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.13) by $0.10. Learn more on analysts' earnings estimate vs. URGN's actual earnings.

How much revenue does UroGen Pharma generate each year?

UroGen Pharma (NASDAQ:URGN) has a recorded annual revenue of $72.52 million.

How much profit does UroGen Pharma generate each year?

UroGen Pharma (NASDAQ:URGN) has a recorded net income of -$109.78 million. URGN has generated -$4.68 earnings per share over the last four quarters.

What is UroGen Pharma's EPS forecast for next year?

UroGen Pharma's earnings are expected to grow from ($3.60) per share to ($2.41) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:URGN) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -